Conference Papers in Science

Conference Paper

Essentials of Oncothermia

Table 3

Summary of the studies made by oncothermia treatment (end points are survival connected).


Study	Number of patients	1st year survival (%)	Median overall survival (m)	Responding patients/ratio (%)	Median overall survival of responding patients (m)	Median overall survival of nonresponding patients (m)	Reference

Brain gliomas	27	86.2	23.6	43	66.2	18.2	[51, 52]
Brain lioma study, phase II	140	71.7
Astrocytoma	40		25.8	80	40.2	20.2	[53, 54]
Glioblastoma	92		16	73	21.*9	13.1	[53, 54]
Diffuse astrocytoma	8		52.9
Glioma (WHO IV) study, phase II, prospective, two arms	45		15
Passive arm	36	40	11				[55, 56]
Active arm	9	65	14.5	43	66.2	18.2
Recurrent glioblastoma study, phase II	19	68.0	21.8	59	32.6	12.4	[57]
Glioma study, phase II	36	60.0
Astrocytoma	9		106				[58]
Glioblastoma	27		20
Glioma study, phase II	179
Astrocytoma	53	100	103				[59]
Glioblastoma	126	76	16
Advanced, relapsed brain gliomas, phase II	12		10	25			[60]
Advanced, relapsed brain gliomas, phase II	24	55	12	25			[61]
Brain glioma WHO III-IV, phase I, safety prospective	24						[62–65]
Metastatic brain tumors study, phase II	15	90.0	46.2	73	48.2	16.1	[60]
Head and neck study, phase II	64	92.2	26.1				[55, 66]
Bone-metastases, monotherapy, phase II	6	100	40.1				[55, 66]
Refractory bone-metastases study, phase II	11			90.9			[67]
Kidney cancer study, phase II	39	84.6	35.9	48	78.4	33.7	[55, 66]
Urinary bladder cancer study, phase II	18	85.0	36.5	73	42.0	22.6	[55]
Nonsmall cell lung cancer meta-analysis	311
Passive arm	53	26.5	14
Active arm	258	67.0	15.8	21	53.4	18.1	[68]
Nonadvanced (WHO < III)	77		11	17
Advanced (WHO ≥ III)	140		14.7	88
Small-cell lung cancer	28
Passive arm	9	29					[69]
Active arm	19	58
Lung carcinoma study, phase II	61	67.2	16.4				[55, 70]
Breast cancers	103	97.1	52.1	45	274.8	10.9	[55, 66]
Soft tissue sarcoma study, phase II	16	100	35.9	31	115.3	31.3	[55]
Esophagus study, phase II	12	41.7	28.5	35	29.4	8.5	[55, 71]
Esophagus study, phase II	7		6.8	100			[72]
Liver metastases from various origin, phase II	25		20.5				[73]
Liver metastases from various origin, comparative study, phase II	28
With radiotherapy	16			81			[67]
With chemotherapy	8			38			[67]
Monotherapy	4			25
Liver metastasis form colorectal origin, phase II	80	86.0	24.1
Passive arm		53	11
Active arm	80	91	24.1				[74]
With chemotherapy	30	80	21.5
Monotherapy	50	92	24.4
Liver metastasis form colorectal origin, phase II	15		23	80			[75]
Liver metastasis form colorectal origin, phase II	22		28				[76]
Liver metastasis	29			86
Liver metastasis form colorectal origin, phase II	30		22				[77]
Pancreas tumor study, phase II	26	46.2	11.6				[78]
Pancreas tumor study, phase II	107
Passive arm	34		6.5				[70]
Active arm	73	52.1	9.93	58	25.5	8.4
Pancreas tumor study, phase II	30	31.0		41	34.4	5.6	[79, 80]
Pancreas tumor study, phase II	42	52.4	12.3				[81]
Pancreas tumor study, phase II	13	40.0	11.9				[82]
Stomach cancer study, phase II	68	58.9	14.4				[55]
Colorectal cancer ()	218	84.9	28.5
Sigma	12			34.1			[55, 66]
Rectum	92			57.1	58	21	[55, 66]
Colon	114			44.2	109.8	23.2
Colon cancer study, phase II, prospective, three arms, randomized	154						[83, 84]
Clifford TCM	53			75			[83, 84]
Monotherapy	50			81
Combined therapy	51			91
Rectum cancer study, Inoperable→operable, phase II	7			71			[72]
Rectal cancer, nonoperable, phase II	65			96			[85]
Pelvic gynecological cancer studies, phase II	74
Cervix	38	86.8	27.6	25	63.5	20.9	[86]
Ovary	27	100	37.8	67	132.7	19.4	[86]
Uterus	9	100	61.5	62	68.5	32.0
Ovary, advanced, relapsed	26						[87]
Heavily pretreated	13		14.3
Not heavily pretreated	13		27
Prostate cancer study, phase II	18	88.9	38.8	72	53.4	7.6	[71]